Hostname: page-component-7857688df4-74lm6 Total loading time: 0 Render date: 2025-11-12T08:21:34.715Z Has data issue: false hasContentIssue false
  • English
  • Français

Behavioral change challenges in limiting fluoroquinolone and extended-spectrum cephalosporins to prevent Clostridioides difficile disease

Published online by Cambridge University Press:  07 August 2020

Christopher J. Graber Open the ORCID record for Christopher J. Graber [Opens in a new window]
Christopher J. Graber*
Affiliation:
Infectious Diseases Section, Veterans’ Affairs Greater Los Angeles Healthcare System, Los Angeles, California David Geffen School of Medicine, University of California, Los Angeles, California
*
Author for correspondence: Christopher J. Graber, E-mail: christopher.graber@va.gov
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Commentary
Information
Infection Control & Hospital Epidemiology , Volume 41 , Issue 10 , October 2020 , pp. 1194 - 1195
Check for updates
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Graber, CJ, Jones, MM, Goetz, MB, et al.Decreases in antimicrobial use associated with multihospital implementation of electronic antimicrobial stewardship tools. Clin Infect Dis 2019. pii: ciz941. doi: 10.1093/cid/ciz941.Google Scholar
Graber, CJ. Clostridium difficile infection: stewardship’s lowest hanging fruit? Lancet Infect Dis 2017;17:123–124.10.1016/S1473-3099(16)30416-9CrossRefGoogle ScholarPubMed
Brown, KA, Langford, B, Schwartz, KL, Diong, C, Garber, G, Daneman, N. Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study. Clin Infect Dis 2020. pii: ciaa124. doi: 10.1093/cid/ciaa124.CrossRefGoogle Scholar
Brown, KA, Khanafer, N, Daneman, N, Fisman, DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother 2013;57:2326–2332.10.1128/AAC.02176-12CrossRefGoogle ScholarPubMed
Slimings, C, Riley, TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881–891.10.1093/jac/dkt477CrossRefGoogle ScholarPubMed
Szymczak, J, Muller, B, Shakamuri, N, et al.Prescriber perceptions of fluoroquinolones, extended-spectrum cephalosporins and Clostridioides difficile infection. Infect Control Hosp Epidemiol 2020;41:914–920.10.1017/ice.2020.183CrossRefGoogle ScholarPubMed
Kahneman, D.Thinking, Fast and Slow. New York: Farrar, Straus, and Giroux; 2011.Google Scholar
Biggest threats and data. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugresistance/biggest-threats.html#cdiff. Accessed April 22, 2020.Google Scholar
Ubel, PA, Rosenthal, MB. Beyond nudges—when improving health calls for greater assertiveness. N Engl J Med 2019;380:309–311.10.1056/NEJMp1806371CrossRefGoogle ScholarPubMed